Colorectal Cancer

Encorafenib, cetuximab, and mFOLFOX6 improved ORR over mFOLFOX6 alone in BRAF V600E-mutant mCRC in the BREAKWATER trial.

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical antitumor activity in patients with refractory metastatic colorectal cancer.

Trifluridine/tipiracil improved DFS in stage IV CRC with molecular residual disease but not in the full ALTAIR study population.

Encorafenib, cetuximab, and mFOLFOX6 improved overall response rate over mFOLFOX6 alone in BRAF V600E-mutant mCRC, per BREAKWATER data.

SCRT plus cadonilimab and chemotherapy showed positive pCRs and acceptable safety in pMMR/MSS locally advanced rectal cancer.

Nivolumab plus ipilimumab significantly improved PFS over nivolumab alone in dMMR/MSI-H metastatic CRC in the CheckMate 8HW trial.

Balstilimab plus botensilimab improved ORR over botensilimab alone in MSS mCRC without liver metastases, per phase 2 data.

Single-cycle neoadjuvant pembrolizumab proved safe and effective in dMMR colon cancer, per RESET-C trial findings.

Aspirin reduced recurrence risk by 50% in PIK3CA-mutated colorectal cancer, per 3-year ALASCCA trial results.

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer.

The combination of encorafenib, cetuximab, and mFOLFOX6 has gained accelerated approval from the FDA for the treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation.

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or refractory microsatellite-stable metastatic colorectal cancer.

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

Jeffrey Wong, MD, discusses findings on the use of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer presented at the 2024 American Society for Radiation Oncology Annual Meeting.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.

An interim analysis of the phase 2 REGINA trial met predefined statistical criteria and suggests the need for further evaluation of the combination of regorafenib, nivolumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

In certain patients, surgical omission, radiotherapy omission, and immunotherapy are being explored.

Mark A. Lewis, MD, discussed the growing excitement of using dostarlimab for the treatment of colorectal cancer and explored ways to maximize its potential.

The FDA has approved adagrasib plus cetuximab for KRAS G12C metastatic colorectal cancer based on data from the KRYSTAL-1 study.

Mark A. Lewis, MD, discusses the exciting progress of dostarlimab in treating rectal cancer.

A clinical complete response was observed in all 42 patients with locally advanced mismatch repair–deficient rectal cancer who completed treatment with the dostarlimab in a phase 2 study.

PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.